

## 15 April 2024

## **Non-executive Director resignation**

Melbourne, Australia, 15 April 2024: dorsaVi (ASX: DVL) (dorsaVi or the Company) advises that Ms Caroline Elliott has tendered her resignation as a Non-executive Director of the Company effective today.

Ms Elliott joined the dorsaVi Board in November 2017 and has been Chair of the Audit & Risk Committee since her appointment, having an instrumental role in ensuring financial governance in the Company.

Michael Panaccio, dorsaVi's Acting Chairman, commented:

"We are extremely grateful for Ms Elliott's contribution to the Company over many years. We would like to thank Caroline and wish her the very best for her future endeavours."

The Board will review potential candidates for Ms Elliott's replacement over the coming months in line with a Board renewal program that was announced to the market at the AGM in 2021.

The release of this announcement was authorised by the Board of dorsaVi.

- ENDS -

## For further information about dorsaVi, please contact:

dorsaViInvestorsAndrew RonchiJoel SeahChief Executive OfficerVesparum Capital+61 417 882 267+61 3 8582 4800ar@dorsavi.comdorsavi@vesparum.com

## About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX listed company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24hours. dorsaVi's focus is on two major markets:

Workplace: dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness
of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi
works either directly with major corporations, or through an insurance company's customer base with the
aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including
Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles,
Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.

• Clinical: dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com